What Melatonin Actually Does

Melatonin is a hormone produced by the pineal gland, a small structure near the center of the brain. Its primary role is not to produce sleep but to broadcast a chemical signal of darkness — a nightly message to the body's circadian system that the light period has ended and the biological night has begun.

Because melatonin sits at the intersection of light exposure, circadian timing, and sleep onset, it is often described as a sleep hormone. That shorthand is partly accurate and partly misleading. Understanding what melatonin actually does — and what it does not do — requires looking at the mechanism in sequence, from the light-sensitive cells that suppress it to the downstream systems it influences.

How Melatonin Is Released and What It Signals

The sequence begins in the retina. Specialized photoreceptive cells — intrinsically photosensitive retinal ganglion cells, or ipRGCs — detect ambient light and relay that information along the retinohypothalamic tract to the suprachiasmatic nucleus (SCN), a paired cluster of roughly 20,000 neurons in the hypothalamus that functions as the brain's master circadian clock. While light reaches the SCN, it suppresses melatonin synthesis in the pineal gland. When light levels fall in the evening, that suppression lifts.

With suppression removed, the pineal gland begins converting serotonin into melatonin through a two-step enzymatic process. Circulating melatonin concentrations, which are very low during daylight hours — typically below 10 picograms per milliliter — begin rising roughly two hours before habitual sleep onset. This rising phase is called dim-light melatonin onset, or DLMO, and it is the most clinically useful marker of an individual's circadian phase. Concentrations peak in the middle of the biological night, often between 2:00 and 4:00 a.m., then fall as dawn approaches and light exposure resumes.

The signal melatonin carries is temporal, not sedative. It binds to MT1 and MT2 receptors distributed across the SCN and other brain regions. MT1 receptor binding suppresses SCN firing, which reduces the circadian arousal drive that keeps the body alert during the day. MT2 receptor binding appears to play a role in phase-shifting the clock itself — adjusting when the circadian system considers "night" to be. Together, these receptor actions create a window of reduced arousal that is permissive of sleep, rather than directly inducing it.

This distinction matters. The adenosine-driven homeostatic sleep pressure that accumulates across waking hours — the mechanism behind what sleep debt actually means at the cellular level — operates on a separate pathway. Melatonin does not increase adenosine. It does not directly initiate slow-wave activity or REM sleep. It adjusts the timing of the gate through which sleep pressure is allowed to express itself.

The Biological Systems That Shape Melatonin's Effect

The suprachiasmatic nucleus. The SCN is both the origin of the signal that triggers melatonin release and a primary target of melatonin's feedback. This bidirectional relationship means that melatonin both responds to the clock and reinforces it, helping stabilize the phase of the circadian rhythm against day-to-day variation in light exposure.

The ipRGC photoreceptors and the light environment. Because melatonin synthesis is gated by light, the spectral composition and intensity of evening light are direct inputs into the system. Short-wavelength (blue-range) light is particularly effective at activating ipRGCs. The relationship between evening light exposure and melatonin suppression is detailed in the discussion of what blue light does to sleep onset. Even relatively modest indoor lighting can delay DLMO if it falls in the blue-spectrum range.

Age-related changes in the pineal gland. The pineal gland accumulates calcium deposits over a lifetime, a process called pineal calcification. Older adults typically show reduced nocturnal melatonin amplitude — lower peak concentrations and a less pronounced rise-and-fall curve. This age-associated attenuation is one reason circadian rhythms tend to become less robust with age, contributing to earlier sleep timing and more fragmented nighttime sleep in older populations.

The autonomic nervous system. Melatonin synthesis is controlled partly by norepinephrine released from sympathetic nerve fibers that innervate the pineal gland. Conditions that chronically elevate sympathetic tone — including certain cardiovascular states and psychological stress — can alter the timing and magnitude of melatonin secretion.

Core body temperature. Melatonin release coincides with the beginning of the nightly drop in core body temperature, which is itself a permissive condition for sleep onset. The two processes are coordinated by the SCN rather than one causing the other, but their co-occurrence means that melatonin's circadian signal arrives alongside a suite of other physiological changes that collectively prepare the body for sleep.

Where the Melatonin Signal Breaks Down or Produces Unexpected Results

Circadian misalignment. When the timing of light exposure, meals, or activity is out of phase with the SCN's internal schedule — as occurs in shift work, transmeridian travel, or irregular sleep timing — melatonin onset can be delayed or advanced relative to the desired sleep window. In these states, the melatonin signal is not absent; it is simply mistimed. The body may feel alert when the clock calls for sleep, or sleepy at socially inconvenient times, because the circadian arousal signal and the behavioral schedule are no longer synchronized.

Delayed sleep-wake phase disorder. In this circadian rhythm disorder, DLMO occurs significantly later than the conventional evening hours — sometimes not until midnight or later. The affected individual is not deficient in melatonin production; the hormone is released normally but at a phase that is chronobiologically late. This is a timing disorder, not a quantity disorder, and it illustrates why measuring melatonin levels at a single point in time provides limited information without knowing where that point falls in the individual's full circadian curve.

Exogenous melatonin and dose complexity. Melatonin is also available as an over-the-counter supplement in many countries. A well-documented complication is that commercially available doses — frequently 3 mg to 10 mg per tablet — can be orders of magnitude higher than the physiological concentrations the pineal gland produces. At supraphysiological doses, circulating melatonin remains elevated well into the following morning, which can produce residual grogginess and, with repeated use, may reduce receptor sensitivity. Research suggests that much smaller doses — in the range of 0.5 mg — are sufficient to shift circadian phase in most adults, but this nuance is often absent from product labeling.

Interaction with the wind-down period. The behavioral and environmental conditions surrounding sleep onset — the gradual dimming of lights, the reduction of cognitive and physical activity — are not separate from melatonin's mechanism. They are, in part, the conditions that allow melatonin to rise without interference. The physiology underlying what a wind-down routine actually does overlaps directly with the light and arousal conditions that shape DLMO timing.

What Measurement Captures About Melatonin — and What It Misses

The clinical standard for measuring melatonin phase is the dim-light melatonin onset protocol. A subject remains in dim light (typically below 10 lux) for several hours in the evening while blood or saliva samples are collected at regular intervals — commonly every 30 to 60 minutes. The time at which melatonin concentration crosses a threshold (often 3 pg/mL in saliva) is recorded as DLMO. This procedure provides a precise circadian phase marker that can be used to time phase-shifting interventions or diagnose circadian rhythm disorders.

Urinary 6-sulphatoxymelatonin, the primary metabolite of melatonin excreted in urine, can be measured from overnight urine collections as an index of total nocturnal melatonin output. This approach is less granular than serial blood sampling but is less invasive and suitable for research settings where exact timing is less critical than aggregate production.

Consumer wearable devices — wrist-worn trackers using photoplethysmography and accelerometry — do not measure melatonin at all. They infer sleep staging from movement patterns and heart rate variability, which are downstream correlates of the circadian and homeostatic processes melatonin influences, not measures of the hormone itself. The gap between what these devices record and what a clinical protocol captures is covered in detail in the discussion of how wearables detect sleep stages.

Even within clinical settings, a single melatonin measurement is rarely interpretable without context. The hormone's concentration is highly sensitive to prior light exposure, the time of day the sample was taken, recent travel across time zones, and the age of the subject. A low reading at 10:00 p.m. in a person who was exposed to bright light until 9:45 p.m. is physiologically expected, not pathological. Meaningful interpretation requires a full profile across the relevant hours, collected under controlled light conditions.

Melatonin is one of the most studied hormones in sleep science, yet its popular reputation as a direct sleep-inducer remains at odds with its actual function as a circadian time-stamp. The pineal gland does not switch sleep on; it marks the onset of biological night, reduces the clock's arousal output, and shifts the phase of the system when conditions change — a more subtle and more consequential role than the common framing suggests.

Note: This explains how sleep works as a system. It is not medical advice, it is not a diagnosis, and it is not a substitute for a licensed healthcare provider. Check the cited sources for current clinical guidance.